Drug Profile
CNTX 2022
Alternative Names: CNTX-2022; Lidocaine gel - Centrexion TherapeuticsLatest Information Update: 20 Jan 2022
Price :
$50
*
At a glance
- Originator Centrexion Therapeutics
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for phase-I development in Pain in Australia (Topical, Gel)
- 09 Feb 2016 Centrexion Therapeutics terminates a phase I trial in Pain in Australia due to limited patient enrolment (NCT02679339)